bims-meluca Biomed News
on Metabolism of non-small cell lung carcinoma
Issue of 2026–11–01
six papers selected by
the Muñoz-Pinedo/Nadal (PReTT) lab, L’Institut d’Investigació Biomèdica de Bellvitge



  1. bioRxiv. 2026 Oct 09. pii: 2026.10.08.757672. [Epub ahead of print]
      Cancer cachexia is a debilitating wasting syndrome associated with involuntary weight loss, reduced appetite and food intake, adipose and muscle atrophy, and systemic inflammation with induction of a myriad of candidate cachexia factors. Using a multi-omic approach in a genetically engineered mouse model of lung cancer cachexia, we found that early circulating metabolic alterations preceded overt weight loss. Although both cachexia and fasting are characterized by a reduction in food intake, we show that the systemic metabolic changes in cachexia are distinct, indicating a lack of induction in the normal protective response to negative energy balance during cachexia. Cancer cachexia causes profound hepatic reprogramming, and activation of inflammatory programs, alongside muscle atrophy and elevation of circulating cytokines. However, targeting individual candidate cachectic factors such as IL-6, TNF-α, GDF15, CCL2, LIF, and IL17A failed to rescue weight loss or prolong survival. In contrast, caloric restriction initiated prior to tumor induction elicited a program of protection during tumor progression that attenuated multi-tissue inflammatory and catabolic transcriptional responses, preserved lean mass, and prolonged survival. Together, these findings suggest that metabolic preconditioning broadly dampens systemic inflammation and delays the onset and progression of cancer cachexia.
    HIGHLIGHTS: Despite both fasting and cachexia involve reduced nutrient intake, the metabolic alterations are distinct.Cachexia induces a systemic inflammatory response.Single targeting of implicated cachectic factors fails to rescue weight loss or survival in cancer cachexia.Caloric restriction pre-conditioning to enforce the protective response to nutrient limitation attenuates cachexia.
    DOI:  https://doi.org/10.64898/2026.10.08.757672
  2. J Cell Commun Signal. 2026 Dec;20(4): e70121
      Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and has emerged as a promising therapeutic target in nonsmall cell lung cancer (NSCLC). However, the specific mechanisms by which nonsmall cell lung cancer cells evade ferroptosis remain to be further elucidated. We conducted integrative transcriptomic analyses of published NSCLC datasets to identify ubiquitin-specific proteases (USPs) potentially involved in the regulation of ferroptosis. Multiple USP proteins were screened and their prognostic significance evaluated, ultimately selecting USP5 for functional studies in two lung adenocarcinoma (LUAD) cell lines and patient-derived LUAD organoids. Following treatment with the ferroptosis inducer erastin, survival rates and metastatic capacity were assessed. Ferroptosis was evaluated by measuring established ferroptotic markers and examining mitochondrial ultrastructure. Protein interactions were investigated using mass spectrometry, immunoprecipitation, and GST pull-down assays. USP5 was significantly upregulated in LUAD tissues and correlated with poor patient prognosis. Functional experiments demonstrated that USP5 suppresses ferroptosis in LUAD cells treated with erastin, thereby promoting cell survival, proliferation, and invasiveness. Mechanistically, USP5 directly binds to and deubiquitinates GPX3, a key antioxidant enzyme, to enhance its stability. Rescue experiments confirmed that GPX3 is a functional mediator of USP5's ferroptosis-inhibitory role. These findings are further supported in patient-derived LUAD organoids. Our study identifies USP5 as a critical suppressor of ferroptosis in LUAD through its stabilization of GPX3, revealing a novel USP5-GPX3 regulatory axis that enables tumor resistance to oxidative stress. Targeting this pathway may represent a promising therapeutic strategy.
    Keywords:  GPX3; USP5; bioinformatics; lung adenocarcinoma; mass spectrum; ubiquitination
    DOI:  https://doi.org/10.1002/ccs3.70121
  3. iScience. 2026 Nov 20. 29(11): 117882
      Lung squamous cell carcinoma (LUSC) has a high mortality rate, creating an urgent need to identify novel therapeutic targets. Aberrant expression of bone morphogenetic protein 2 (BMP2) is associated with the progression of several cancers. Previous reports demonstrated that BMP2 is highly expressed in tumor tissues and serum of patients with non-small cell lung cancer (NSCLC). However, the pathological roles and mechanisms of BMP2 in LUSC progression, and the mechanism underlying the overexpression of BMP2 remain to be elucidated. In this study, we found that a high level of BMP2 is correlated with poor prognosis in patients with LUSC, and that BMP2 promotes the growth and metastasis of LUSC cells in vitro and in vivo by activating the MAPK-ERK1/2 signaling pathway. The expression of BMP2 is transcriptionally repressed by the transcription factor GATA6. In conclusion, our findings demonstrate that BMP2 may serve as a potential therapeutic target for the treatment of LUSC.
    Keywords:  BMP2; GATA-binding factor 6; GATA6; LUSC; bone morphogenetic protein 2; lung squamous cell carcinoma; migration; proliferation
    DOI:  https://doi.org/10.1016/j.isci.2026.117882
  4. J Cardiothorac Surg. 2026 Aug 03. pii: 864. [Epub ahead of print]21(1):
       BACKGROUND: This study aims to comprehensively evaluate the expression pattern of PSMD12 in lung adenocarcinoma (LUAD) and its impact on prognosis, and to explore its potential application value in the diagnosis and treatment of LUAD.
    METHODS: This study employed bioinformatics analysis and molecular biology experiments to comprehensively investigate the expression pattern of the PSMD12 gene in LUAD and its association with LUAD patients' clinical features. First, we evaluated the differential expression of PSMD12 in 44 different tumor types and its relationship with the prognosis of LUAD patients. GO, KEGG, and GSEA were used to analyze the function of PSMD12. Secondly, TIMER was applied to evaluated the relationship between PSMD12 gene expression and immune infiltration characteristics in LUAD patients. Finally, RT-qPCR, CCK-8, clone formation assay, wound healing assay, and Transwell assay were used to verify the effects of knockdown PSMD12 expression on the proliferation, migration, and invasion abilities of LUAD cells.
    RESULTS: Survival analysis results showed that high PSMD12 gene expression levels were significantly correlated with the poor prognosis of LUAD patients. The importance of PSMD12 in key metabolic pathways and disease processes such as neuroactive ligand-receptor interaction, taste and olfactory transduction, and steroid hormone biosynthesis was revealed. Immune infiltration analysis results showed that PSMD12 expression was negatively correlated with M2 macrophages, revealing the potential role of PSMD12 in regulating the immune microenvironment of LUAD. In vitro experiments verified the functional role of the PSMD12 in LUAD cells, indicating that knockdown of PSMD12 weakened the proliferation, migration, and invasion abilities of LUAD A549 and H1299 cells.
    CONCLUSIONS: High expression of PSMD12 may be closely related to poor prognosis in LUAD patients and promotes the malignant progression of LUAD by enhancing the proliferation, migration, and invasion of LUAD cells.
    Keywords:  Cell migration and invasion; Immune infiltration; Lung adenocarcinoma; PSMD12; Prognosis
    DOI:  https://doi.org/10.1186/s13019-026-04601-z
  5. Proteomes. 2026 Oct 02. pii: 52. [Epub ahead of print]14(4):
       BACKGROUND: Lung adenocarcinoma (LUAD) shows marked heterogeneity in its immune microenvironment, which may contribute to differences in disease-free survival (DFS) and clinical outcome. Although current LUAD classifications are largely based on genomic or transcriptomic features, immune subtypes defined directly from bulk proteomic data remain poorly characterized. Here, we used an immune-cell proteomic reference matrix to investigate proteome-defined immune states in LUAD and to identify prognostically relevant immune subtypes.
    METHODS: A quantitative human immune-cell proteomic reference matrix was integrated with LUAD tumor proteomic profiles. The reference matrix covered seven major immune lineages and 26 immune-cell states. The discovery cohort included 101 LUAD tumor proteomes with matched clinical information. After gene symbol matching and normalization, proteome-defined immune-cell state signals were estimated for each sample using non-negative constrained regression. These signals were then used for unsupervised subtype identification and DFS analysis. An independent Clinical Proteomic Tumor Analysis Consortium (CPTAC)-LUAD cohort was used for validation, with subtype analysis performed at the immune-cell marker protein module level.
    RESULTS: The immune-cell reference matrix contained 8400 quantified proteins, and 2381 proteins were retained for modeling. Based on 26 proteome-defined immune-cell state signals, LUAD samples separated into two immune proteomic subtypes. In the discovery cohort, Subtype 2 had significantly worse DFS than Subtype 1 (log-rank p = 0.0047; HR = 2.09, 95% CI 1.24-3.54). In the Clinical Proteomic Tumor Analysis Consortium (CPTAC)-LUAD validation cohort, marker protein module-based analysis again identified two subtypes with distinct DFS outcomes. The high-risk Subtype 2 showed higher Granulocyte and Myeloid/DC modules, whereas the low-risk Subtype 1 showed higher B cell, T cell, and NK-cell modules. Subtype 2 was associated with shorter DFS in the validation cohort (log-rank p = 0.0061; HR = 3.45, 95% CI: 1.35-8.82), and this association remained significant after adjustment for age, sex, and stage.
    CONCLUSIONS: Proteomic immune profiling identified two prognostically distinct immune subtypes in LUAD. The poor-DFS subtype was characterized by increased myeloid/granulocyte-related protein modules, whereas the favorable-DFS subtype showed stronger B cell-, T cell-, and NK cell-related signals. These findings support the use of bulk tumor proteomics to characterize clinically relevant immune heterogeneity in LUAD.
    Keywords:  CPTAC; disease-free survival; immune infiltration; immune subtype; lung adenocarcinoma; proteomics; tumor microenvironment
    DOI:  https://doi.org/10.3390/proteomes14040052
  6. Adv Biol Regul. 2026 Oct 27. pii: S2212-4926(26)00046-1. [Epub ahead of print]102 101189
      Lactic acid is increasingly recognized as a signaling molecule that influences cellular behavior and the tumor microenvironment. Lysophosphatidic acid (LPA) receptor signaling regulates diverse malignant properties of cancer cells, but its relationship with long-term lactic acid exposure remains unclear. Here, we investigated LPA receptor-mediated cellular responses using lung cancer A549 cells chronically exposed to lactic acid (A549-LA), established by stepwise treatment with 0.1-5 mM lactic acid for approximately 2 months. A549-LA cells exhibited enhanced proliferation and motility, together with increased LPAR1 and LPAR3 and reduced LPAR2 expression compared with parental cells. LPA promoted growth in A549-LA cells but suppressed growth in parental cells, while pharmacological analyses revealed distinct effects of LPA1, LPA2, and LPA3 on growth and motility. Notably, A549-LA cells exhibited higher viability than parental A549 cells during CDDP treatment, and LPA further increased the viability of A549-LA cells. A549-LA cells also showed reduced monocarboxylate transporter 1 (MCT1) and MCT4 expression, decreased extracellular lactate levels, and lower intracellular ATP levels. Inhibition of MCT1 or lactate dehydrogenase suppressed LPA-induced growth while enhancing motility and reducing viability during CDDP treatment. Under glucose-depleted conditions, A549-LA cells maintained proliferative capacity, which was further enhanced by LPA and suppressed by inhibition of lactate metabolism. These findings indicate that long-term lactic acid exposure alters LPA receptor signaling and lactate metabolism, thereby reshaping cellular responses and the balance between growth, motility, and CDDP response in lung cancer cells.
    Keywords:  Cellular functions; LPA receptors; Lactic acid; Lung cancer cells; Lysophosphatidic acid
    DOI:  https://doi.org/10.1016/j.jbior.2026.101189